Shield Therapeutics notes UK launch of Feraccru® by Norgine
Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, is pleased to note the announcement today by Norgine that they have launched Feraccru® in the UK. Feraccru® is a novel, effective and well tolerated treatment for Iron Deficiency in adults. In September 2018, Shield licensed Feraccru® to Norgine B.V. in most European territories.
Carl Sterritt, Chief Executive Officer of Shield Therapeutics, added: “I am delighted that Norgine’s UK team is now starting to promote Feraccru® in the UK. Since announcing the licence agreement in September 2018, we have been working closely with Norgine to transfer knowledge and responsibilities from Shield to them and the UK launch demonstrates that this transition period is progressing well.”